Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study for FILSPARI in FSGS at the ERA 2026 Congress. Patients who remained on FILSPARI for up to five years maintained durable proteinuria reductions, with 37.5% achieving complete remission and 87.5% achieving partial remission.
Key figures
- Drug Name
- FILSPARI (sparsentan)
- Phase Of Trial
- Phase 3
- Patient count
- 371
- Ole duration years
- 3
- Study duration years
- 5
- Partial remission switchers
- 74.6%
- Complete remission switchers
- 28.9%
- Partial remission filspari initiators
- 87.5%
- Complete remission filspari initiators
- 37.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.